- Accelerated, sequential testing (e.g., ASTM, ISTA) is no longer acceptable by the FDA for drug product testing
- Real-world testing cannot test the “worst-case” edges of your operating space
- Real-world testing in the post-COVID-19 world will be difficult and expensive
